Findings by researchers from Stanford University Medical Center and published in the Journal of Clinical Oncology suggest that survivors of pediatric Hodgkin's lymphoma need to remain vigilant about their health even thirty years after their initial diagnosis.
Researchers examined 110 pediatric Hodgkin's lymphoma survivors between 1970 and 1990 who were treated with low-dose radiation and chemotherapy. During a median follow-up of 20.6 years, they found that 18 of those patients had developed at least one secondary cancer, ranging from leukemia to carcinomas of the breast or thyroid.
In sum, they found that the risk of secondary cancers for these patients at 20 years was 17 percent and at 30 years, nearly 30 percent.
Source: Leukemia & Lymphoma Society
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...